Related Experiment Videos
Hereditary angio-oedema: its pathogenesis and management
Insights
Hereditary angio-oedema is a genetic disorder typically caused by C1-inhibitor deficiency or dysfunction. This review covers its pathogenesis, clinical aspects, and the scientific basis for current and emerging therapies.
Area of Science:
- Immunology
- Genetics
- Pharmacology
Background:
- Hereditary angio-oedema (HAP) is a rare genetic disorder.
- It is primarily linked to C1-inhibitor (C1-INH) deficiency or dysfunctional C1-INH.
- C1-INH plays a crucial role in regulating inflammatory pathways.
Purpose of the Study:
- To review the pathogenesis and clinical manifestations of hereditary angio-oedema.
- To discuss the homeostatic functions of C1-inhibitor.
- To describe current and novel therapeutic strategies for HAE.
Main Methods:
- Literature review of hereditary angio-oedema.
- Analysis of C1-inhibitor's role in homeostasis.
- Evaluation of existing and emerging treatment modalities.
Main Results:
- HAE pathogenesis involves dysregulation of the complement and kinin-kallikrein systems.
- Clinical features include recurrent episodes of swelling.
- C1-inhibitor replacement therapy and other treatments aim to restore homeostasis.
Conclusions:
- Understanding C1-inhibitor's function is key to managing HAE.
- Therapeutic approaches are evolving, targeting specific pathways.
- Further research into HAE pathogenesis and treatment is ongoing.
Abstract:
Hereditary angio-oedema is a genetically-determined disease. Usually the disease is due to a deficiency of C1-inhibitor or less commonly to the production of a functionally inactive molecule. The pathogenesis and clinical features of the disease are reviewed, and discussed in relation to the homeostatic role of C1 inhibitor. Finally the therapeutic approach to the disease is described and the scientific bases for the newer therapeutic discussed.